Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease. Reply

N Engl J Med. 2024 May 2;390(17):1634-1635. doi: 10.1056/NEJMc2402472.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols* / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
  • Cyclophosphamide / adverse effects
  • Cyclophosphamide / therapeutic use
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell* / blood
  • Leukemia, Lymphocytic, Chronic, B-Cell* / diagnosis
  • Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy
  • Leukemia, Lymphocytic, Chronic, B-Cell* / pathology
  • Neoplasm, Residual* / blood
  • Neoplasm, Residual* / diagnosis
  • Randomized Controlled Trials as Topic
  • Rituximab / adverse effects
  • Rituximab / therapeutic use
  • Survival Analysis

Substances

  • ibrutinib
  • venetoclax
  • fludarabine
  • Cyclophosphamide
  • Rituximab